l General Information |
Product Name | Combretastatin A4 |
General description | Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM. |
Synonym | 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; Combretastatin-A4; Crc 87-09; NSC 817373 |
Purity | ≥99%(HPLC) | CAS Number | 117048-59-6 |
Formula | C18H20O5 | Molecular Weight | 316.353 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | ≥20mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Combretastatin A4 is a vascular disrupting agent (VDA) that targets tumor vasculature to inhibit angiogenesis. It inhibits tubulin polymerization at the colchicine-binding site of beta-tubulin. It has antitumor activity by inhibiting AKT function in human gastric cells. The inhibited AKT activation causes decreased cell proliferation, cell cycle arrest, and reduced in vitro migration/invasiveness and in vivo metastatic ability. Combretastatin A4 is a natural stilbenoid phenol. |
Application | Antineoplastic Agents, Phytogenic |
l Packaging & Storage |
Packaging | 25mg; 100mg; 500mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
